A Study to Evaluate the Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients


About this study

The purpose of this study is to evaluate the clinical outcomes of the Micropulse Trans-Scleral Cyclophotocoagulation Laser (MPTSCPC) after 1 day, 1 week,1 month, 3 months, 6 months and one year of follow-up. Its primary objective is to conduct a prospective observational study on the efficacy of using MP-TSCPC to treat glaucoma patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Healthy adult subjects who weigh at least 110 lbs.
  • Non-pregnant.

Exclusion Criteria:

  • Adults who weigh less than 110 lbs.
  • Pregnant adults.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Syril Dorairaj, M.B.B.S., M.D.

Contact us for the latest status

Contact information:

Renata Prota Hussein



More information


Publications are currently not available

Mayo Clinic Footer